Followers | 828 |
Posts | 119585 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Monday, December 23, 2019 3:23:55 PM
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
Ubrelvy may do well in the crowded CGRP arena because it’s oral.
AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.
AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM